Could a Two-Drug punch before surgery shrink head & neck tumors?

NCT ID NCT06980038

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the combo or the single drug for a short time before their planned surgery. The main goal is to see if the combo leads to a major reduction in viable tumor tissue and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Los Angeles General Medical Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact Email: •••••@•••••

  • Ochsner Medical Center Jefferson

    RECRUITING

    New Orleans, Louisiana, 70121, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • VCU Massey Comprehensive Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.